Artificial Intelligence Market Insights: Invenio Imaging Inc. On-Site Study for Lung Cancer Detection

Invenio Imaging Inc. has initiated a pivotal trial for its Artificial intelligence ( AI)-based image analysis module aimed at detecting Lung cancer . The On - Site study is a multicenter trial being conducted at prestigious institutions including the University of Texas MD Anderson Cancer Center , Corewell Health , Memorial Sloan Kettering Cancer Center , and the University of North Carolina at Chapel Hill , in collaboration with Johnson & Johnson Enterprise Innovation . The study seeks to develop the first FDA - cleared AI for identifying cell / tissue morphology suspicious of cancer in lung biopsies , a crucial milestone for Invenio Imaging Inc.

The NIO Laser Imaging System by Invenio is the focal point of the On - Site study , designed to assist physicians in detecting cancer in bronchoscopic lung biopsies where rapid onsite tissue evaluation ( ROSE ) may not be available . Due to resource limitations , many centers performing lung biopsy lack the capability of ROSE , and the NIO system aims to extend the benefits of ROSE to the proceduralist when the service is not accessible . This innovative technology offers the potential to streamline the detection process and improve outcomes for patients undergoing lung cancer screening.

The ON - SITE study is supported by the National Cancer Institute of the U.S. National Institutes of Health , under award No . 1R44CA281581 - 01 , emphasizing the importance and potential impact of this research in the field of lung cancer detection . Invenio Imaging Inc. is at the forefront of developing cutting - edge AI solutions that have the potential to revolutionize the way lung cancer is diagnosed and treated in the future.

In a collaborative effort with pharmaceutical giant Johnson & Johnson , Invenio Imaging Inc. has embarked on a multi - center trial to test its NIO Laser Imaging System for lung cancer detection . The trial , known as the ON - SITE study , is being conducted at two universities in Texas and North Carolina , with the goal of developing an AI - based image analysis module that assists in the detection of cancer in bronchoscopic lung biopsies . Through this trial , Invenio hopes to obtain FDA clearance for its AI - driven software to identify lung cancer , marking a significant advancement in medical imaging technology.

The potential of AI in healthcare is rapidly evolving , with technologies like the NIO system offering the promise of fast , accurate identification of cancerous tissue . Principal investigator Gustavo Cumbo - Nacheli believes that AI has the potential to improve outcomes , cost - benefit profiles , and personalized treatments in the field of healthcare . As the ON - SITE study progresses , it is expected to pave the way for more efficient and effective lung cancer detection methods , benefiting patients and healthcare providers alike.